Abstract:In the general population, selective cyclooxygenase (COX)-2 inhibitors have been associated with fewer gastrointestinal adverse effects (AEs) than NSAIDs, but whether they are associated with exacerbations in patients with inflammatory bowel disease (IBD) remains controversial.The aim of this study was to review published and unpublished findings to determine whether the use of COX-2 inhibitors increased the risk for IBD exacerbations relative to placebo in the treatment of IBD.A systematic search of MEDLINE (1966-July 2007), EMBASE (1980-July 2007), the Cochrane Library (2007 Issue 4), US Food and Drug Administration records, and data on file at Novartis Pharmaceuticals Corporation, Pfizer US Pharmaceutical Group, and Merck & Co., Inc., using the search terms celecoxib, rofecoxib, valdecoxib, etoricoxib, lumiracoxib, cyclooxygenase 2 inhibitor, Crohn's disease, ulcerative colitis, and inflammatory bowel disease, was performed to identify randomized, placebo-controlled clinical trials of 5 COX-2 inhibitors in patients with IBD. The publications were fully reviewed for quality. Data on trial design, patient characteristics, intervention drugs, dosages, and outcomes were collected using a predetermined data-extraction form. A meta-analysis was performed based on the publications that met the inclusion/exclusion criteria.Of 588 studies identified in the electronic search, 574 were excluded after screening the titles and abstracts. Fourteen related to the use of COX-2 inhibitors in patients with IBD were reviewed. Two randomized, controlled trials comparing COX-2 inhibitors with placebo were identified. In the first trial, 82 patients were randomized to receive etoricoxib (60-120 mg/d) and 77 to receive placebo. The exacerbation rates were 10.5% (8/76) in the active-treatment group and 11.4% (8/70) in the placebo group (relative risk [RR], 0.92; 95% CI, 0.37-2.32). In the second trial, 112 patients were treated with celecoxib (200 mg BID) and 110 received placebo. The exacerbation rates were 3.7% (4/107) in the celecoxib group and 2.7% (3/110) in the placebo group (RR, 0.73; 95% CI, 0.17-3.18). Of these patients, 5 were lost to follow-up because of AEs. In the meta-analysis comparing COX-2 inhibitors and placebo, the RR was 0.86 (95% CI, 0.39-1.88). No statistically significant differences in IBD relapse rates were found between COX-2 inhibitors and placebo.The results from this meta-analysis suggest that insufficient data were available to determine the impact of COX-2 inhibitors on IBD exacerbations. The relatively smaller risk for AEs makes the short-term use of COX-2 inhibitors potentially attractive, but the long-term benefits remain unclear. Further studies with sound methodology and large sample sizes are needed to evaluate the tolerability of COX-2 inhibitors in the treatment of IBD.

Systematic review with meta-analysis: the gastrointestinal benefits of COX-2 selective inhibitors with concomitant use of low-dose aspirin.

Risks of Colorectal Neoplasms and Cardiovascular Thromboembolic Events after the Combined Use of Selective COX-2 Inhibitors and Aspirin with 5-Year Follow-Up: a Meta-Analysis

Systematic Review with Network Meta-Analysis: Comparative Effectiveness and Safety of Strategies for Preventing NSAID-associated Gastrointestinal Toxicity

Effects of Cyclooxygenase-2 Inhibitors on Gastrointestinal Malignancies: a Systematic Review and Meta-analysis

Network Meta-Analysis Comparing Relatively Selective Cox-2 Inhibitors Versus Coxibs For The Prevention Of Nsaid-Induced Gastrointestinal Injury

Meta-analysis: cyclooxygenase-2 inhibitors are no better than nonselective nonsteroidal anti-inflammatory drugs with proton pump inhibitors in regard to gastrointestinal adverse events in osteoarthritis and rheumatoid arthritis.

Review Article: Low‐dose Aspirin, Non‐steroidal Anti‐inflammatory Drugs and Cyclo‐oxygenase Inhibitors – Balancing Risks and Benefits

Systematic review of non-steroidal anti-inflammatory drugs reduce the risk of gastric cancer

[Selective COX-2 Inhibitor Versus Nonselective COX-1 and COX-2 Inhibitor in the Prevention of Heterotopic Ossification after Total Hip Arthroplasty: a Meta-Analysis of Randomised Trials].

Nonsteroidal Anti‐Inflammatory Drug‐Gastropathy and Enteropathy

Efficacy and Safety of COX-2 Inhibitor and NSAID Combined with PPI in the Treatment of Gastrointestinal Adverse Reactions in Patients with Knee Joint Disease

114 Combination of a Cyclooxygenase (COX)-2 Selective NSAID and a Proton Pump Inhibitor for Prevention of Gastroduodenal Ulcers in Very High Risk Patients: A One-Year, Double-Blind, Randomized Trial

The Effects of Anti-inflammatory Drug Treatment in Gastric Cancer Prevention: an Update of a Meta-analysis.

Gastrointestinal Safety of Celecoxib Versus Naproxen in Patients with Cardiothrombotic Diseases and Arthritis after Upper Gastrointestinal Bleeding (CONCERN): an Industry-Independent, Double-Blind, Double-Dummy, Randomised Trial

Meta-analysis on the Relationship Between Nonsteroidal Anti-Inflammatory Drug Use and Gastric Cancer.

Role of Selective Cyclooxygenase-2 Inhibitors in Exacerbation of Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

Association of COX-inhibitors with cancer patients' survival under chemotherapy and radiotherapy regimens: a real-world data retrospective cohort analysis

Expressions and significance of COX-1 and COX-2 in low-dose Aspirin associated gastric mucosal lesions

Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications--review and recommendations based on risk assessment.

Efficacy and Safety of Concomitant Use of Proton Pump Inhibitors with Aspirin-Clopidogrel Dual Antiplatelet Therapy in Coronary Heart Disease: A Systematic Review and Meta-Analysis

Aspirin and non-steroidal anti-inflammatory drugs use reduce gastric cancer risk: A dose-response meta-analysis